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Background:Mitochondrial proapoptotic proteins such as SMAC, HtrA2, and ARTS promote apoptosis by antagonizing
the inhibitor of apoptosis proteins (IAPs).
Results: A novel anti-apoptotic E3 ubiquitin ligase, AREL1 was cloned and identified to interact with and ubiquitinate the IAP
antagonists.
Conclusion: AREL1 inhibits apoptosis through ubiquitinating the cytosolic IAP antagonists.
Significance: AREL1-mediated degradation of IAP antagonists represents a new anti-apoptotic signaling pathway.
Identification of new anti-apoptotic genes is important for
understanding the molecular mechanisms underlying apoptosis
and tumorigenesis. The present study identified a novel anti-apo-
ptoticgenenamedAREL1,whichencodesaHECT(homologous to
E6-APcarboxyl terminus) family E3ubiquitin ligase.AREL1 inter-
acted with and ubiquitinated IAP antagonists such as SMAC,
HtrA2, and ARTS. However, AREL1 was cytosolic and did not
localize to nuclei or mitochondria. The interactions between
AREL1 and the IAP antagonists were specific for apoptosis-stimu-
lated cells, in which the IAP antagonists were released into the
cytosol from mitochondria. Furthermore, the ubiquitination and
degradation of SMAC, HtrA2, and ARTS were significantly
enhanced in AREL1-expressing cells following apoptotic stimula-
tion, indicating that AREL1 binds to and ubiquitinates cytosolic
but not mitochondria-associated forms of IAP antagonists. Fur-
thermore, the anti-apoptotic role ofAREL1-mediateddegradation
of SMAC, HtrA2, and ARTS was shown by simultaneous knock-
down of three IAP antagonists, which caused the inhibition of
caspase-3 cleavage, XIAPdegradation, and induction of apoptosis.
Therefore, the present study suggests that AREL1-mediated ubiq-
uitination and degradation of cytosolic forms of three IAP antago-
nists plays an important role in the regulation of apoptosis.
Apoptosis, or programmed cell death, can be induced
through two basic and distinct signaling pathways: intrinsic and
extrinsic apoptosis signaling pathways. Both of these pathways
culminate in proteolytic activation of the caspase protease fam-
ily (1). Because proteolytic cleavage is irreversible and caspases
can amplify proteolysis cascades, caspase activation is tightly
regulated. The only known cellular caspase inhibitors aremem-
bers of the inhibitor of apoptosis (IAP)3 family that commonly
contain baculoviral repeat (BIR) domains and, in some cases, a
zinc RING finger domain (2, 3). Recent studies suggest that the
X-linked inhibitor of apoptosis (XIAP) is a bona fide caspase
inhibitor because it exhibits greater potency than other IAPs (4,
5). The anti-apoptotic functions of XIAP are apparent in cancer
chemotherapy, as the frequent overexpression of XIAP inmany
human tumors confers chemoresistance, and knocking out
XIAP restores chemosensitivity (6).
The caspase-inhibitory functions of XIAP are negatively reg-
ulated by endogenous inhibitors that were originally identified
inDrosophila such as Reaper, Hid, and Grim, which commonly
contain an N-terminal IAP-binding motif that is required for
IAP binding (7). In mammals, SMAC and HtrA2 were identi-
fied as IAP-binding motif domain mitochondrial IAP antago-
nists that are released into the cytosol from the intermembrane
space in mitochondria in response to apoptosis signals (8–12).
However, recent studies have revealed that SMACandHtrA2 tar-
get many proteins involved in various signaling pathways rather
than regulation of the catalytic activity of caspases through XIAP
(6). ARTS and XAF1 preferentially interact with XIAP. ARTS,
which normally resides in mitochondria but moves to the cytosol
upon apoptotic stimulation, does not contain an IAP-binding
motif but preferentially binds to and promotes the ubiquitination
and degradation of XIAP (13). XAF1 was identified as a nuclear
protein that binds to XIAP, thereby sequestering XIAP in nuclear
inclusions (14). In the present study, we identified a novel anti-
apoptotic E3 ubiquitin ligase, AREL1,4which targetsmitochon-
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drial pro-apoptotic proteins SMAC, HtrA2, and ARTS (but not
XAF1), only when they are released into the cytosol upon apo-
ptotic stimulation.
EXPERIMENTAL PROCEDURES
Functional cDNA Cloning Strategy—The osteosarcoma cell
line SaOs-2was transfectedwith a cDNA library constructed by
cloning mouse testis cDNA into a  pCEV29 expression vector
to enhance DNA integration into chromosomes and decrease
variations in cDNA expression (15). Approximately 2,000 sta-
ble transfectants were obtained from each 100mm transfection
plate after G418 selection, with a total of 300,000 independ-
ent transfectants generated. The G418-resistant colonies,
which reached a diameter of 1 mm, were then infected with a
recombinant adenovirus encoding p53 (16). Surviving colonies
were transferred to new dishes and cultured. Plasmid DNAwas
isolated from the genomic DNA of the surviving cells as
described previously (15).
Cell Culture and DNA Transfection—The pcDNA6-V5/His
vector (Invitrogen) was used for the transient expression of
cDNAs. Transfection efficiency was monitored by cotransfec-
tion with aRenilla luciferase vector (pRL-CMV; Promega). The
retroviral vectors for the expression of cDNAs or shRNAs were
constructed using pBABE-puro. Two mutant constructs that
lacked the ability to form a ubiquitin-thioester complex,
AREL1C790A and AREL1- HC790A, were generated using a
QuikChange site-directed mutagenesis kit (Stratagene). All
constructs were verified by sequencing the entire coding
region. siRNA oligonucleotides corresponding to the
sequences of AREL1 (5-AATTGGTCCCTGAGAACCTTT-
3), HtrA2 (5-GGGGAGUUUGUUGUUGCCAdTdT-3),
SMAC (5-GUCAGAGAGAGGAGUCCUU-3), and ARTS
(5-CGTAGTGATGGGACACCATTT-3) were generated
and used for transfection with Lipofectamine RNAiMAX
(Invitrogen). Scrambled siRNAwas obtained fromProligo LLC.
Yeast Two-hybrid Screen—The yeast cell-expressing LexA-
HECT (amino acids 454–823 of AREL1) was transformed with
the mouse brain cDNA library fused to the GAL4-AD. The
yeast two-hybrid system,Matchmaker LexA two hybrid system
(Clontech), was used to detect AREL1-interacting proteins.
Positive cloneswere initially selected and then assayed for-ga-
lactosidase activity using a filter assay. Positive clones were
identified by using the polymerase chain reaction followed by
sequence analysis.
Western Blot Analysis and Immunoprecipitation—Western
blot and immunoprecipitation analyses were performed as
described previously (17) using the following antibodies:
anti-XIAP (BD Pharmingen); anti-cleaved caspase-3 and anti-
survivin (Cell Signaling Technology); anti-procaspase 3, anti-
Hsp60, anti-HtrA2, anti-SMAC/DIABLO, anti--actin, anti--
tubulin, and anti-ubiquitin (Santa Cruz Biotechnology);
anti-V5 (Invitrogen); and anti-FLAG (Sigma). Polyclonal rabbit
anti-AREL1 antibodies were generated against a synthetic pep-
tide that encompassed amino acid residues 796–807 by
Abfrontier and amino acids 521–534 by Zymed Laboratories,
Inc.. Primary antibody binding was detected using horseradish
peroxidase-conjugated goat anti-mouse, goat anti-rabbit, or don-
key anti-goat secondary antibodies in combination with an
enhanced chemiluminescence system (Amersham Biosciences).
In Vitro Ubiquitination Assay—For the ubiquitin binding
assays, 5 g of purified GST-AREL1-H protein was added to
ubiquitin binding mixtures that contained 80 ng of E1 (Calbi-
ochem), 500 ng of E2 (GST-UbcH5a, Calbiochem), and 5 g of
ubiquitin (Sigma) in a ubiquitination buffer (50 mM Tris-HCl
(pH 7.4), 2 mM ATP, 5 mMMgCl2, 0.5 mM DTT, 1 mM creatine
phosphate, and 15 units of creatine phosphokinase). For the in
vitro ubiquitination of XIAP antagonists by AREL1, 1 g each
of purified SMAC or HtrA2 (BD Biosciences) was added to
ubiquitination reaction mixtures containing 0.5 g of GST-
AREL1-H. Reactions were incubated for 90min at 30 °C, termi-
nated by the addition of SDS sample buffer, and resolved by
SDS-PAGE.
Apoptosis Assays—Apoptotic sensitivity was determined by
twomethods. Cell viability was assessed using a tetrazolium salt
(WST-8)-based colorimetric assay from theCell CountingKit 8
(Dojindo, Kumamoto, Japan) (18) or by a trypan blue and pro-
pidium iodide exclusion assay (19).
FIGURE 1. Functional cDNAcloningof anovel anti-apoptotic E3ubiquitin
ligase.A, functional cDNAcloning strategy for isolatingcDNAswhoseexpres-
sion confers resistance top53-inducedapoptosis.B, schematic comparisonof
the HECT domain of AREL1 with that of known HECT family E3 ubiquitin (Ub)
ligases. The HECT, filamin, WW, and C2 (Ca2-binding motif) domains are
indicatedby black, shaded, striped, and open boxes, respectively. The right side
of the diagram shows the percentage of amino acids that are identical or
similar (referred to as “positive”) between the HECT domain of AREL1 and
each of the known E3 ubiquitin ligase HECT domains. C, in vitro E3 ubiquitin
ligase activity of AREL1-HECT proteins. GST-HECT proteins were incubated in
the presence of E1, E2, ubiquitin, and ATP. The positions of the ubiquitin
adducts on the GST-HECT protein are indicated.
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Statistical Analysis—The data were represented as mean 
S.E. of the indicated number of measurements. Statistical sig-
nificance was calculated by two-tailed unpaired t test for two
data sets and analysis of variance followed by Bonferroni post
hoc test for multiple data sets using SPSS18, with p  0.05
considered statistically significant.
RESULTS
Functional cDNACloning of a Novel Anti-apoptotic E3Ubiq-
uitin Ligase, AREL1—A cDNA expression cloning strategy was
developed to isolate new anti-apoptotic genes (Fig. 1A).
Approximately 300,000 independent transfectants were
obtained from the human osteosarcoma cell line SaOs-2 after
transfection with a cDNA expression library as described pre-
viously (15). A recombinant adenovirus encoding p53 was
infected into G418-resistant colonies to induce apoptosis (16).
Surviving transfectants were rare and appeared at a frequency
of 103. cDNAs were isolated from the transfectants, and
their ability to inhibit apoptosis was examined. Of the cDNAs
isolated from surviving cells, a 2.4-kb cDNA (originally named
9–31) comprising 342 C-terminal amino acids and encoded by
a mouse full-length cDNA (RIKEN cDNA 1110018G07) was
identified, which was almost identical (97%) to the human
homolog (KIAA0317). This gene was designated AREL1 (apo-
ptosis-resistant, E3 ubiquitin ligase). The location of AREL1
was identified on chromosome 14q24.3, spanning 51,853 bp
and 20 exons. Northern blotting showed that 5.4 kb of AREL1
mRNA was detected in various mouse tissues such as brain,
testes, heart, liver, lung, and kidney, but barely in skeletal mus-
cle and spleen (data not shown).
AREL1 contains a C-terminal HECT (homologous to E6AP
C terminus)-like domain that is similar to the C termini of E3
ubiquitin ligases such as E6-AP (20), Nedd4 (21), SMURF2 (22),
and PUB1 (Fig. 1B) (23). Therefore, we next examined the abil-
ity of the HECT-like domain of human AREL1 to accept ubiq-
uitin from an E2 ubiquitin-conjugating enzyme through a thio-
ester bond. Similar to previous findings showing that theHECT
domain of E3 ubiquitin ligases is sufficient for enzymatic activ-
ity (20), a fusion protein of GST with the HECT domain of
FIGURE 2. AREL1 inhibits both p53-dependent and -independent apoptosis. A, AREL1 suppresses p53- and staurosporine-induced apoptosis in p53-
deficient SaOs-2 cells. SaOs-2 cells were transfected with the indicated plasmids and then either infected with 50 MOI (multiplicity of infection) of adenovirus
encoding p53 or staurosporine (STS, 30 nM) for 24 h. Cell viability was assessed by colorimetric assay kit (Cell Counting Kit-8) based onMTT assay. The reported
values represent the means S.E. of three independent experiments performed in duplicate. *, p 0.01; **, p 0.005; ***, p 0.001 versus vector control in
each case. B, AREL1 suppresses p53- and staurosporine-induced apoptosis in p53-positive U2OS cells. U2OS cells were transfectedwith the indicated plasmids
and were then infected with either the p53-encoding adenovirus or staurosporine as in A. Cell viability was assessed as in A. C–E, AREL1 inhibits apoptosis of
U2OS (p53/) cells treated with staurosporine (30 nM) (C), H1299 (p53/) cells treated with etoposide (50 M) (D), and HCT116 (p53/) cells treated with
doxorubicin (1 M) (E). Cells were transfected with an empty control vector (pcDNA6), wild type AREL1, or AREL1C790A and then treated with the indicated
apoptosis stimuli for the indicated times. Cell viability was assessed as described in A.
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AREL1 (AREL1-H, comprising amino acids 454 to 823) showed
auto-ubiquitination activity in the presence of E1, E2 (UbcH5a),
ubiquitin, and ATP (Fig. 1C). The formation of AREL1-H ubiq-
uitin adducts was inhibited by DTT, which disrupts thioester
complex formation (Fig. 1C). HECT E3 ubiquitin ligases con-
tain a highly conserved cysteine residue that is essential for the
acceptance of ubiquitin from E2 enzymes (20, 24). AREL1-
HC790A, in which cysteine 790 was replaced by alanine, failed to
form an ubiquitin thioester complex (Fig. 1C). These results
indicate that AREL1 encodes a HECT family E3 ubiquitin
ligase.
To investigate the anti-apoptotic function ofAREL1, apopto-
tic sensitivity was examined in SaOs-2 cells transiently trans-
fected with human full-length AREL1, the HECT domain of
AREL1 (AREL1-H), or Bcl-xL as a positive control (Fig. 2A).
Cells transfected with AREL1, AREL1-H, or Bcl-xL exhibited a
similar level of resistance to p53-induced apoptotic death (Fig.
2A). To further investigate whether E3 ubiquitin ligase activity
is important for the anti-apoptotic functions of AREL1, U2OS
cells, which express wild-type p53, were transiently transfected
with AREL1C790A or AREL1-HC790A, or with their wild-type
counterparts, AREL1 or AREL1-H. AlthoughU2OS cells trans-
fected with AREL1 or AREL1-HECT were resistant to p53-in-
duced apoptosis, those transfected with AREL1C790A or
AREL1-HC790A were as sensitive as control cells (Fig. 2B), sug-
gesting that the E3 ubiquitin ligase activity of AREL1 is essential
for the inhibition of apoptosis.
However, AREL1 also inhibited apoptosis of SaOs-2 and
U2OS cells treated with staurosporine (Fig. 2, A–C), an agent
that induces p53-independent apoptosis (25). Furthermore,
AREL1 inhibited apoptosis in p53-deficient H1299 and p53-
positive HCT116 cells treated with DNA-damaging agents
doxorubicin and etoposide, respectively (Fig. 2,D and E), suggest-
ing that AREL1 inhibits both p53-dependent and -independent
apoptosis. Inaddition,AREL1didnot affect thecytosolic releaseof
cytochrome c from mitochondria upon apoptotic stimulation
(data not shown) (see Fig. 4B). These results led us to examine
downstream of the mitochondrial apoptotic pathway that are
activated following cytosolic release of mitochondrial proapo-
ptotic proteins.
AREL1 Binds to and Ubiquitinates the Cytosolic Forms of
SMAC, HtrA2, and ARTS—The hypothesis that AREL1 is able
to inhibit downstream regulators of themitochondrial pathway
was supported by a yeast two-hybrid screen, inwhich theHECT
domain of AREL1 was used as a bait protein. Among the posi-
tive clones that interact withAREL1-HECT in yeast two-hybrid
screening, a cDNA encoding HtrA2 was of particular interest
because of its proapoptotic functions in the cytosol (10, 11). A
GST pulldown assay confirmed the interaction of AREL1-
HECTwith HtrA2 (Fig. 3A). The interactions of AREL1-HECT
with IAPs and their inhibitors, including SMAC, ARTS, and
XAF-1, were further examined. Interestingly, SMACandARTS
was also found to interact with AREL1-HECT, but XAF-1 and
IAPs (XIAP, cIAP1/2, and survivin) were not (Fig. 3A).
Immunofluorescence analysis showed that AREL1 localized
to the cytoplasmnot tomitochondria or nuclei (Fig. 3,B andC).
Because three IAP antagonists such as SMAC, HtrA2, and
ARTS reside in the mitochondria of healthy cells but are
released into the cytosol upon apoptotic stimulation, AREL1
may interact with cytosolic forms of SMAC, HtrA2, and ARTS
but not with the mitochondria-associated forms of these pro-
teins. To examine this idea, cells were treated with etoposide to
release the IAP antagonists into the cytosol, and the in vivo
interactions were examined byWestern blot analysis of immu-
noprecipitated fractions. Endogenous AREL1 interacted with
SMAC, HtrA2, and ARTS in etoposide-treated cells but not in
healthy cells (Fig. 3D). Therefore, these results suggest that
AREL1 interacts with the cytosolic forms of SMAC,HtrA2, and
ARTS upon apoptotic stimulation but does not associate with
mitochondria-localized proteins in healthy cells.
Based on the apoptosis-specific interaction between AREL1
and cytosolic forms of the IAP antagonists, we next examined
whether AREL1 directly ubiquitinated those proteins. An in
vitro ubiquitination assay indicated that AREL1-HECT directly
FIGURE 3.AREL1 interactswith IAP antagonists in the cytosol. A, GST pull-
down assay. Pulldowns were performed using extracts of H1299 cells and
were followed by Western blotting with the indicated antibodies. The input
loaded represents 5% of the total protein. B, subcellular localization of AREL1
(green) was assessed in H1299 cells by immunofluorescence staining with
polyclonal anti-AREL1 serum (1:100). DAPI (blue) and MitoTracker (red) were
used to stain nuclei and mitochondria, respectively. Scale bar is 100 m.
C, AREL1 in the cytosolic fractions. H1299 cells were fractionated into soluble
cytosolic, nuclear, andmitochondrial fractions.Westernblot analysiswasper-
formedwith the indicated antibodies. Tubulin, lamin B, andHSP60were used
to confirm the purity of each subcellular fraction.D, immunoprecipitation (IP)
and Western blot analysis. Cell extracts were prepared 6 h after treatment
with etoposide and subjected to either Western blotting or immunoprecipi-
tation/Western blot analysis.WCE, whole cell extract.
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ubiquitinated all three proteins in the presence of E1, E2, and
ATP (Fig. 4A). To further investigate whether AREL1 specifi-
cally promotes the degradation of the cytosolic forms of the IAP
antagonists, cytosolic fractionswere prepared fromH1299 cells
transfected with AREL1 or an empty vector to examine the
protein levels of SMAC, HtrA2, and ARTS.
Consistent with previous reports showing that SMAC,
HtrA2, and ARTS are released into the cytosol along with cyto-
chrome c (26), the cytosolic forms of the mitochondrial pro-
apoptotic proteins increased upon treatment with etoposide
(Fig. 4B). However, this increase in cytosolic forms of SMAC,
HtrA2, and ARTS was not observed in AREL1-expressing cells
(Fig. 4B). Furthermore, a proteasome inhibitor, MG132 inhib-
ited the degradation of cytosolic forms of the IAP antagonists in
AREL1-expressing cells (Fig. 4B), implying that AREL1 pro-
motes proteasomal degradation of the cytosolic SMAC, HtrA2,
and ARTS. In addition, the half-life of a SMAC mutant
(SMAC76), which lacks the IAP-bindingmotif andmitochon-
drial import signals and localized at the cytosol (27), was clearly
shortened by AREL1 (Fig. 4C).
We next examined the ubiquitination of endogenous SMAC,
HtrA2, and ARTS by AREL1. Ubiquitination of the IAP antag-
onists was detected in H1299 cells treated with etoposide and
was significantly increased in AREL1-expressing cells com-
pared with vector-transfected cells (Fig. 4D). Therefore, these
results suggest that AREL1 binds to and ubiquitinates SMAC,
HtrA2, and ARTS, resulting in the degradation of their cytoso-
lic forms after their release from mitochondria following apo-
ptosis stimulation.
Anti-apoptotic Functions of AREL1-mediatedUbiquitination
of the IAP Antagonists—To evaluate the functional significance
of AREL1-mediated ubiquitination of the three IAP antago-
nists, we next examined the effects of simultaneous knockdown
of the three IAP antagonists on apoptosis induction, XIAP deg-
radation, and caspase-3 cleavage. Knockdown of any one of the
IAP antagonists in H1299 cells did not confer apoptotic resist-
ance; however, knockdown of all three IAP antagonists con-
ferred a level of apoptotic resistance that was similar to that
observed after AREL1 overexpression (Fig. 5A). The knock-
down of any two of the IAP antagonists was less effective than
the knockdown of all of the IAP antagonists (Fig. 5A). The triple
knockdown also conferred apoptosis resistance to U2OS and
HCT116 cells treated with staurosporine and doxorubicin,
respectively (Fig. 5, B and C). Because XIAP is the most potent
caspase inhibitor among IAP family proteins and a common
cytosolic target for SMAC,HtrA2, andARTS (26, 28), we exam-
ined the influence of the triple knockdown on XIAP and
caspase-3. XIAP degradation and caspase-3 cleavage were
detected in etoposide-treated H1299 cells, staurosporine-
treated U2OS cells, and doxorubicin-treatedHCT116 cells, but
these were significantly suppressed by the knockdown of the
three IAP antagonists (Fig. 5,D–F). Furthermore, the inhibition
of XIAP degradation was also seen in AREL1-expressing cells
(Fig. 5G). In addition, the effects of AREL1 knockdown were
examined. In contrast to AREL1 overexpression, AREL1
knockdown increased apoptotic sensitivity in etoposide-
treated H1299 cells, staurosporine-treated U2OS cells, and
doxorubicin-treated HCT116 cells (Fig. 6, A–C). Furthermore,
the AREL1 knockdown enhanced XIAP degradation and
caspase-3 cleavage (Fig. 6, D–F), further supporting anti-apo-
ptosis functions of AREL1. Therefore, these results suggest that
AREL1-mediated ubiquitination and degradation of the cyto-
solic forms of the three IAP antagonists contributes to the inhi-
FIGURE 4. AREL1 targets the cytosolic forms of SMAC, HtrA2, and ARTS. A, in vitro ubiquitination of ARTS, HtrA2, and SMAC by AREL1-HECT. GST-HECT
proteins were incubated with the indicated proteins in the presence of E1, E2, ubiquitin (Ub), and ATP. Arrowheads indicate non-ubiquitinated proteins.
Caspase-3 (Casp-3) was used as a negative control. B, AREL1 targets the cytosolic forms of the IAP antagonists. Total cell extracts and subcellular fractions
(mitochondrial (mito) and cytosolic) were prepared fromH1299 cells transfected with empty vector (pcDNA6) or AREL1 treated with etoposide (20M) for 6 h
in the presence or absence of MG132 (10 M) and used for Western blotting with the indicated antibodies. C, AREL1 shortened the half-life of cytosolic SMAC
proteins. A FLAG-tagged SMAC mutant (SMAC76) was transfected with AREL1 or an empty vector. The SMAC76 proteins were detected with anti-FLAG
antibody after treatmentwith cycloheximide (10g/ml). The half-life of the SMACproteins was calculated to be2 h in HCT116 cells, but shorter than 0.5 h in
AREL1-expressing cells.D, ubiquitination of endogenous XIAP in AREL1-expressing cells. H1299 cells transfected with AREL1 or an empty vector were treated
with etoposide (20M) for 6 h in the presence of a proteasome inhibitor,MG132 (10M), and then lysedwith denaturation buffer containing 6MUrea followed
by immunoprecipitation and Western blotting with the indicated antibodies. Cntl, control.
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bition of apoptosis induction, XIAP degradation, and caspase-3
activation.
DISCUSSION
In the present study, we cloned and identified a novel anti-
apoptotic E3 ubiquitin ligase, AREL1, which binds to and ubiq-
uitinates the IAP antagonists, SMAC, HtrA2, and ARTS
released into the cytosol upon apoptotic stimulation (Figs.
1–4). Because simultaneous knockdown for three IAP antago-
nists inhibited apoptosis induction as well as caspase-3 activa-
tion and XIAP degradation (Fig. 5), AREL1-mediated ubiquiti-
nation of the IAP antagonists will contribute apoptotic
resistance in human tumor cells treated with DNA damaging
agents.
Although AREL1 was originally identified as a suppressor of
p53-induced apoptosis (Fig. 1A), overexpression ofAREL1 con-
ferred apoptotic resistance to staurosporine in both p53-pos-
itive and -deficient tumor cells (Fig. 2). Furthermore, apo-
ptosis induced by DNA damaging agents such as etoposide
and doxorubicin in p53-deficient H1299 and p53-positive
HCT116 cells was also suppressed by AREL1 expression (Fig.
2). Because AREL1 did not affect the cytosolic release of
mitochondrial proapoptotic proteins such as cytochrome c
(Fig. 4B) but inhibited caspase-3 activation (Fig. 5F), we
examined whether AREL1 influences a downstream pathway
that is activated following mitochondrial outer membrane
permeabilization. Furthermore, based on the results of two
hybrid screens and GST pulldown assays (Fig. 3A), we found
that AREL1 binds to and ubiquitinates the cytosolic forms of
the IAP antagonists but not mitochondrial-associated pro-
teins (Figs. 3 and 4).
Certain cell lines show resistance to apoptosis after knock-
down of SMAC,HtrA2, or ARTS (9, 13, 29). However, the pres-
FIGURE 5. Anti-apoptotic effects of simultaneous knockdown of three IAP antagonists. A, apoptotic sensitivity of H1299 cells transfected with siRNAs
directed against one, two, or three IAP antagonists following treatment with etoposide for 24 h. Viability was assessed using the Cell Counting Kit-8 assay.
Reported values represent the means S.E. of three independent experiments performed in duplicate. *, p 0.01; **, p 0.005; ***, p 0.001 versus siRNA
control (siCntl). B and C, apoptosis of U2OS and HCT116 cells that were transfected with siRNAs against three IAP antagonists following treated with stauro-
sporine and doxorubicin (Dox), respectively, for 24 h. Viability was assessed as described in A. D–F, the effects of triple knockdown on XIAP degradation and
caspase-3 cleavage. H1299, U2OS, and HCT116 cells were transfected with a mixture of siRNAs against SMAC, HtrA2, and ARTS for 12 h and then treated with
etoposide, staurosporine, and doxorubicin, respectively. Cytosolic andmitochondrial (mito) fractionswere prepared 6 h after treatmentwith apoptosis stimuli
and analyzed by Western blotting with the indicated antibodies. F, inhibition of XIAP degradation and caspase-3 (Casp-3) cleavage by AREL1. H1299 cells
transfected with AREL1 or an empty vector were treated with etoposide (20 M) for the indicated times, and then analyzed by Western blotting with the
indicated antibodies. Cntl., control.
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ent study showed that knockdown of all three IAP antagonists
exerted a stronger anti-apoptosis effect than knockdown of any
one or two of three IAP antagonists (Fig. 5), implying that the
three IAP antagonists are functionally redundant with respect
to each other in tumor cells tested. Therefore, these results
suggest that degradation of three IAP antagonists by AREL1
may confer apoptotic resistance upon a wider range of tumor
cells that require two or more IAP antagonists for apoptosis
induction.
The cytosolic forms of mitochondrial IAP antagonists target
many proteins involved in various signaling pathways. SMAC
binds to and promotes the degradation of cIAP1/2, which reg-
ulates both the classical and alternative NF-B signaling path-
ways rather than the catalytic activity of caspases (6). However,
cIAP1/2 degradation was not prominent in many types of
tumor cells such as H1299, A549, or 293T cells upon treatment
with apoptotic stimuli (data not shown). These results coincide
with a recent report showing that many human tumor cell
lines do not appear to be sensitive to SMAC mimetic chem-
ical compounds, which cause a loss of both cIAP1 and -2 and
enhance the sensitivity to TNF-induced apoptosis in cer-
tain tumor cells (30). Therefore, the effects of AREL1 on
cIAP1/2 stability need to be studied in other experiment
systems, in which endogenous SMAC proteins efficiently
target cIAP1/2. Like SMAC, HtrA2 also targets many pro-
teins located in the cytosol and within mitochondria (29).
Because AREL1 interacted with HtrA2 released into the
cytosol, but not with mitochondria-associated proteins,
cytosolic targets of HtrA2 may be influenced by AREL1.
Therefore, the E3 ubiquitin ligase activity of AREL1 for the
three IAP antagonists may influence many of the regulatory
pathways involved in apoptosis, depending on the tumor cell
context and the type of apoptotic stimuli.
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